Literature DB >> 15381201

A novel polymorphism of the gene encoding furin, a TGF-beta1 activator, and the influence on cardiac allograft vasculopathy formation.

C G Densem1, A-S M Mutlak, V Pravica, N H Brooks, N Yonan, I V Hutchinson.   

Abstract

BACKGROUND: Coronary vasculopathy (CV) is an important determinant of survival following cardiac transplantation. We have previously shown that G915C polymorphism of the Transforming Growth Factor-beta1 (TGF-beta1) gene strongly influences CV development. Furin is a proprotein convertase enzyme important in TGF-beta1 activation. We investigated for polymorphism within the promoter region of the gene for furin (fur). Allelic variation of the fur gene, in conjunction with TGF-beta1 polymorphism, was subsequently related to the development of CV. METHODS AND
RESULTS: The fur gene promoter region (position -1199 to +39) was analysed by SSCP and sequencing. A C/T single nucleotide substitution polymorphism at position -231* was identified. Using PCR the fur and TGFB1 genotypes were identified in 115 cardiac transplant recipients. CV was diagnosed at routine surveillance post-transplant coronary angiography. Fur polymorphism had no influence on vasculopathy development; median time to diagnosis, *C/C homozygotes, 2.27 years (2.10-4.32), *C/T heterozygotes 2.97 years (2.09-4.24), *T/T homozygotes 2.65 years (2.33-4.08), (P=0.95). Allelic variation did not influence Kaplan Meier actuarial analysis of disease onset (P=0.54). Ninety-three percent of recipients were high TGF-beta1 producers. We used fur polymorphism to substratify patients with the +915*G/G TGFB1 (high producing) allele. Fur polymorphism did not influence CV development within this TGF-beta1 high producer cohort, when analysed by time to first diagnosis and Kaplan Meier testing.
CONCLUSIONS: We have described a novel polymorphism at position -231* in the gene encoding furin. The fur -231* single nucleotide polymorphism in isolation, or in conjunction with TGFB1 polymorphism, is not useful as a genetic risk marker for cardiac transplant associated coronary vasculopathy.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15381201     DOI: 10.1016/j.trim.2004.04.005

Source DB:  PubMed          Journal:  Transpl Immunol        ISSN: 0966-3274            Impact factor:   1.708


  3 in total

1.  Transforming growth factor-beta polymorphisms and cardiac allograft rejection.

Authors:  Raymond L Benza; Christopher S Coffey; Dawn M Pekarek; Joseph P Barchue; Jose A Tallaj; Michael J Passineau; Hernan E Grenett
Journal:  J Heart Lung Transplant       Date:  2009-10       Impact factor: 10.247

2.  The clinical value of enzyme-multiplied immunoassay technique monitoring the plasma concentrations of cyclosporine A after renal transplantation.

Authors:  Xiao-Hui Luo; Wu-Jun Xue; Pu-Xun Tian; Xiao-Ming Ding; Hang Yan; He-Li Xiang; Yang Li
Journal:  J Pharm Anal       Date:  2012-01-30

3.  Contribution of the polymorphism rs1800469 of transforming growth factor β in the development of myocardial infarction: meta-analysis of 5460 cases and 8413 controls (MOOSE-compliant article).

Authors:  Ling Du; Tao Gong; Minghui Yao; Henghua Dai; Hong Gang Ren; Haitao Wang
Journal:  Medicine (Baltimore)       Date:  2019-06       Impact factor: 1.817

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.